SNPX - יחס חוב להיוון בספרים Synaptogenix Inc.

Synaptogenix, Inc. (SNPX) is driving its stock price trajectory through an innovative approach to neural connection regeneration. The development of Briostatin-1 to combat dementia, combined with R&D cost control and stable liquidity, supports business resilience. The ratio of the company's financial debt to balance sheet equity illustrates the asset's financial architecture, where 0.00 determines the current value of the metric, allowing for an assessment of the debt load relative to equity.

This ratio determines the degree of capital structure dependence on borrowed funds relative to the equity balance. The calculation logic identifies bankruptcy risk or excessive conservatism in asset management. Analyzing the percentage of debt participation in balance sheet capital allows for an assessment of financial stability during restructuring periods. For Synaptogenix, Inc. (SNPX), a low debt load confirms the clinical trial outsourcing model. Minimizing internal capital expenditures through vendors reduces the need for leverage.